Spots Global Cancer Trial Database for Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Official Title: Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission

Study ID: NCT00963521

Conditions

Leukemia

Interventions

therapeutic autologous dendritic cells

Study Description

Brief Summary: RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with acute myeloid leukemia in complete remission.

Detailed Description: OBJECTIVES: Primary * Assess the tolerability of autologous dendritic cell vaccine in patients with acute myelogenous leukemia in complete remission. Secondary * Evaluate the emergence of an immune response. * Determine the relapse rate. * Assess the occurrence of residual disease. OUTLINE: Patients receive increasing doses of blastic cells transformed in vitro by autologous dendritic cells (1/3 subcutaneously and 2/3 IV) every 3 weeks for up to 5 doses.